DAFTAR PUSTAKA

1. Palmer J, Perunovic P, Tidy J, Review Endometrial Hyperplasia. The

Obstetrician & Gynaecologist 2008;10:211216.
2. Reed S.D, Newton K.M. et al. Incidence Of Endometrial
Hyperplasia. Am J Obstet Gynecol. 2009; 200 (6): 678.
3. Montgomery B. Daum G. Dunton C. Endometrial Hyperplasia: A
Review. Obstetrical and Gynecological Survey. 2004: 368-376
4. Trimble C et al. Management of Endometrial Precancers. The American
Collage of Obstetricians and Gynecologist Vol. 120, No.5: 11601172
5. Vaskivuo T. Tumor Necrosis Factor-, and NF-B in Human Endometrial
Hyperplasia and Carcinoma. Obstetric and Gynecology University of
Oulu. 2002. 1463-1471
6. Boise et al. Bcl-x, a Bcl-2 related gene that functions as a dominant
regulator of apoptotic cell death. Cell. 1993; 74: 597-608
7. Busmianis I. Ho T, Tan S, Khoo K. P53 and Bcl-2 Expression in
Invasive and Pre-Invasive Uterine Papillary Serous Carcinoma and
Atrophic Endometrium. Annual Academy Medicine Singapore.
2005:34:423-424
8. Loffe OB, Papadimetriou JC,et al. Correlation of proliferation
indices,apoptosis, and related oncogene expression (bcl-2 and cerbB-2) and p53 in proliferative, hyperplastic, and malignant
endometrium. Hum Pathol 1998;29(10):1150-9
9. Kokawa K, Yagi S, et al. Apoptosis andthe expression of Bax and
Bcl-2

in

hyperplasia

and

adenocarcinoma

of

the

uterine

endometrium. Hum Reprod 2001;16:2211-18

10. Gewies A. Introduction to Apoptosis. Aporeview. 2003: 1-26.
11. Bronchud, M.H., 2004. BCL2 in : Principle of Molecular Oncology,
2nd Ed. Humana Press. p. 82-85.

56
Universitas Sumatera Utara

12. Elmore S, Apoptosis : Riview of programmed cell death. Toxicol

Patol, 2007; 2007; 35 (4): 495 516
13. Ignae HF, Peter H.K, death and anti death : resistance to apoptosis,
Nature review.2002. Vol 2: 277 288
14. Sheau, Y. S and Aaron J.W.H., 2000. Tissue specific bcl-2 protein
partners in apoptosis: An ovarian paradigm. Physiological review
vol 80, No 2, pp. 593-610
15. Walensky, L.D., 2008. Multimodal Targeting of the BCL-2 family in
Cancer. American Association for Cancer Research Education
Book. http://educationbook.aacrjournals.org
16. Taylor R, Sean P, Seamous J. Apoptosis : Controlloed demolition at
the cellular level. Nature review. 2008. Vol 9.231 241
17. Yoshimura S, Banno T et al. Ceramid Formation Leads to Caspase
3 Activation During Hypoxic PC12 Cell Death. Inhibitory Effect of
Bcl-2

onCerami

Formation

and

Caspase-3

Activation.

J.Biol.Chem.273:6921-6927
18. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in
cancer therapy. CA Cancer J Clin 2005;55:178-94
19. Chang H.Y and Yang X 2000. Proteases for cell Suicide : Functions
and regulation of caspase. Microbiol. Mol.Biol. Rev.64:821-846
20. Wong R.S Apoptosis in cancer : from pathogenesis to treatment.
Journal of Experimental & Clinical Cancer Research, 2011,30 :87
21. De vita, Rosenberg S. Cancer Principal & Practice of oncology
th

Book 1,7 . Lippincot William and Wilkins,@ 005 : 95 102

22. Rautureau, G.J.P., Catherine, L., Mark, G. H,. 2010. Intrinsically
Disordered Proteins in Bcl-2 Regulated Apoptosis. International
Journal Molecular Sciences,11 :1808-1824.
23. Kumar, Robbins,

Leonard,

S.,

Vinay, 2010.

Neoplasia

in:

Robbins&Cotran Pathologic Basis of Disease, 8th ed. Philadelphia:

Saunders Elsevier: 269-342.

57
Universitas Sumatera Utara

24. Daniel N.N, Krosmeyer, S.J 2004. Cell death : Critical control Points
Cell.116 : 205-219
25. Cory, S. and Adams, J.M., 2002. The Bcl2 family: regulators of the
cellular life-or-death switch. Nat Rev Cancer 2, pp. 647.
26. Guset G et al. Bcl-2 Expression in Endometrial Carcinoma in Relation to
Different Histopathologic Prognostic Factors. Journal of Experimental
Medical Surgical Research. 2010: 251-254. Bcl 2 inhibit onkogen
27. Krysko D, Berghe T, Herde K, Vandenabeele P. Apoptosis and
Necrosis: Detection, Discrimination and Phagocytosis. 2007. 205-220
28. Karunananda A. Management of Atypical Endometrial Hyperplasia.
European International Journal of Applied Science and Technology.
2014. 1-5.
29. Steinbakk A et al. Molecular Biomarkers in Endometrial Hyperplasias
Predict Cancer Progression. American Journal of Obstetric and
Gynecology. 2011:375.e2.
30. Dorjgochoo T et al. Association of Genetic Markers in Bcl-2 Family of
Apoptosis-Related Gees with Endometrial Cancer Risk in a Chinese
Population. 2013: 1-2
31. Driak D. Changes in Expression of Some Apoptotic Markers in
Different Types of Human Endometrium. Read periodical. 2011.1.
32. Elmer P. Image-based Quantification of Apoptosis-Driven Nuclear
Fragmentation using the Opera. Perkin Elmer. USA. Jan 2010: 1-3.
33. Aylyyon.V, Cayla.X, et al. Bcl-2 Targets Protein Phosphatase
1 to Bad. TJOI. 2014: 1-9.
34. Boise et al. Bcl-x, a Bcl-2 related gene that functions as a
dominant regulator of apoptotic cell death. Cell. 1993; 74: 597608.
35. Sarmadi et al. Immunohistochemical expression of estrogen and
progesterone receptors in endometrial hyperplasia and
endometrioid carcinoma. Tehran University Medical Journal.
2012; 70 (3): 156-161.

58

Universitas Sumatera Utara

36. Upson K,Allison K.H, et al. Biomarkers of progestin therapy

resistance and endometrial hyperplasia progression. Am. J. Obstet
Gynecol. NIH. 2012; 207 (1): 36-38.
37. Dorjgochoo T,Xiang Y.B,et al. Association of Genetic Markers in the
BCL-2 Family of Apoptosis-Related Genes with Endometrial Cancer
Risk in a Chinese Population. PLOS. 2013; 8 (4): 1-9.
38. Cahyanti RD. Bcl-2 dan Indeks Apoptosis pada Hyperplasia
Endometrium Non Atipik Simpleks dan Kompleks. Undip. 2008: 188
39. Barhoom S. Sharom A. Bcl-2 proteins link programmed cell death
with growth and morphogenetic adaptations in the fungal plant
pathogen Colletotrichum gloeosporioides. Departement of Plant
Science. 2006; 22: 32-43.
40. Santoso D. Apoptosis Index Between Females And Males In
Reguler Hemodialysis. Media Clinical Pathology and Medical
Laboratory. 2013; 19 (3):P 1-2.
41. Teguh M. Mose J.C,et al. Perbedaan Indeks Apoptosis Plasenta
Antara Preeklamsi dan Kehamilan Normal serta Hubungannya
dengan Berat Badan Lahir dan Tekanan Darah Ibu. Bagian Obstetri
dan Ginecologi. FK.Unpad. 2010; 42 (1): 1-5.
42. Gao G. Dou P. G1 Phase-Dependent Expression of Bcl-2 mRNA
and Protein Correlates with Chemoresistance of Human Cancer
Cells. The American Society for Pharmacology and Experimental
Therapeutics. 2000; 58 (5): 1-10.
43. Strik H. Deininger M.et al. BCL-2 Family protein expression in initial
and recurrent glioblastomas: modulation by radiochemotherapy. J
Neurol Neurosurg Psychiatry. 1999; 67: 763-768.
44. Ikegaki N, Katsumata M,et al. Expression of bcl-2 in Small Cell
Lung Carcinoma Cells. American Association for cancer Research.
February 2014; 54: 6-8.

59

Universitas Sumatera Utara

45. Ribeiro M.D, Countinho L.M, The Role Of Apoptosis, Cell

Proliferation Index, BCL-2, and P53 in Glioblastoma Prognosis. Arq
Neuropsiquiatr. 2004; 62 (2): 262-270
46. Hardian et al. Apoptosis Index, Expression p53, Bcl-2,and
Angiogenesis in Reccurence Endometrial Hyperplasia Patients.
Undip
47. Marsden E Donald, Hacker F Neville. The Classification, Diagnosis
and

Management

of

Endometrial

Hyperplasia.

Review

in

Gynaecological faktor yang mempengaruhi Practice 3 (2003)89-97

48. Goncharenko et al. Predictive Diagnosis of Endometrial Hyperplasia
and Personalized Therapeutic Strategy in Women of Fertile Age. The
EPMA Journal. 2013: 14
49. Hannemann M, Alexander H, Cope N, Acheson N, Phillips A.
Endometrial Hyperplasia: a Clinicals Review. Obstetrics, Gunaecology
and Reproductive Medicine. 2014: 116-119
50. Allred D, Breast Center, Assestment of Prognostic and Predictive
Factors in Breast Cancer by Immunohistochemistry. Baylor College of
Medicine. (2006): 4-5

60

Universitas Sumatera Utara